Wambolt & Associates LLC Sells 533 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Wambolt & Associates LLC lessened its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 33.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,077 shares of the medical equipment provider’s stock after selling 533 shares during the period. Wambolt & Associates LLC’s holdings in Intuitive Surgical were worth $425,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. Diversify Advisory Services LLC purchased a new stake in Intuitive Surgical in the 1st quarter worth approximately $2,862,000. Private Advisor Group LLC lifted its stake in Intuitive Surgical by 9.1% in the first quarter. Private Advisor Group LLC now owns 11,873 shares of the medical equipment provider’s stock worth $4,738,000 after acquiring an additional 987 shares during the period. Norden Group LLC boosted its holdings in Intuitive Surgical by 32.4% in the first quarter. Norden Group LLC now owns 957 shares of the medical equipment provider’s stock valued at $382,000 after acquiring an additional 234 shares in the last quarter. Dillon & Associates Inc. increased its position in Intuitive Surgical by 0.6% during the 1st quarter. Dillon & Associates Inc. now owns 23,706 shares of the medical equipment provider’s stock valued at $9,459,000 after purchasing an additional 144 shares during the period. Finally, Van ECK Associates Corp raised its holdings in Intuitive Surgical by 2.1% in the 1st quarter. Van ECK Associates Corp now owns 57,675 shares of the medical equipment provider’s stock worth $23,017,000 after purchasing an additional 1,162 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, EVP Myriam Curet sold 5,318 shares of the business’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the completion of the sale, the executive vice president now directly owns 298 shares in the company, valued at approximately $110,456.68. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Craig H. Barratt sold 1,400 shares of the company’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $421.06, for a total value of $589,484.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Myriam Curet sold 5,318 shares of Intuitive Surgical stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total value of $1,971,169.88. Following the transaction, the executive vice president now owns 298 shares in the company, valued at $110,456.68. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,956 shares of company stock worth $6,927,011. 0.80% of the stock is owned by insiders.

Intuitive Surgical Stock Up 2.1 %

Shares of NASDAQ ISRG traded up $8.95 during trading on Friday, reaching $443.76. 1,114,523 shares of the company traded hands, compared to its average volume of 1,317,312. The firm has a 50 day simple moving average of $410.21 and a 200-day simple moving average of $386.57. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $448.10. The stock has a market capitalization of $157.40 billion, a PE ratio of 80.10, a P/E/G ratio of 5.62 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm’s quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter last year, the company posted $1.00 earnings per share. As a group, research analysts predict that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ISRG. Stifel Nicolaus increased their price target on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Citigroup raised their target price on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Evercore ISI increased their price objective on Intuitive Surgical from $385.00 to $425.00 and gave the stock an “in-line” rating in a report on Tuesday. Robert W. Baird dropped their target price on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a report on Friday, April 19th. Finally, Piper Sandler increased their price target on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research note on Friday, April 19th. Six equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and an average target price of $404.79.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.